BEAM vs. NTLA
BEAM (Beam Therapeutics Inc.) and NTLA (Intellia Therapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, BEAM returned -16.23%/yr vs -28.38%/yr for NTLA. A 0.71 correlation means they provide meaningful diversification when combined.
Performance
BEAM vs. NTLA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BEAM achieves a 28.17% return, which is significantly lower than NTLA's 75.19% return.
BEAM
- 1D
- 4.07%
- 1M
- 24.06%
- YTD
- 28.17%
- 6M
- 27.26%
- 1Y
- 111.99%
- 3Y*
- 3.76%
- 5Y*
- -16.23%
- 10Y*
- —
NTLA
- 1D
- 0.51%
- 1M
- 25.00%
- YTD
- 75.19%
- 6M
- 62.37%
- 1Y
- 71.20%
- 3Y*
- -27.29%
- 5Y*
- -28.38%
- 10Y*
- -4.95%
BEAM vs. NTLA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
BEAM Beam Therapeutics Inc. | 28.17% | 11.77% | -8.89% | -30.40% | -50.92% | -2.39% | 240.17% |
NTLA Intellia Therapeutics, Inc. | 75.19% | -22.90% | -61.76% | -12.61% | -70.49% | 117.35% | 272.60% |
Correlation
The correlation between BEAM and NTLA is 0.69, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.69 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.71 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.76 |
Correlation (All Time) Calculated using the full available price history since Feb 6, 2020 | 0.71 |
The correlation between BEAM and NTLA has been stable across timeframes, ranging from 0.69 to 0.76 - a consistent structural relationship.
Fundamentals
BEAM:
$3.67B
NTLA:
$1.87B
BEAM:
-$0.63
NTLA:
-$3.58
BEAM:
27.72
NTLA:
26.26
BEAM:
3.15
NTLA:
3.01
BEAM:
$132.27M
NTLA:
$66.09M
BEAM:
-$84.92M
NTLA:
-$33.92M
BEAM:
-$68.39M
NTLA:
-$299.32M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BEAM vs. NTLA — Risk / Return Rank
BEAM
NTLA
BEAM vs. NTLA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Beam Therapeutics Inc. (BEAM) and Intellia Therapeutics, Inc. (NTLA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BEAM | NTLA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.77 | ||
| Sortino ratioReturn per unit of downside risk | +0.84 | ||
| Omega ratioGain probability vs. loss probability | 1.27 | 1.22 | +0.05 |
| Calmar ratioReturn relative to maximum drawdown | 2.95 | 1.00 | +1.95 |
| Martin ratioReturn relative to average drawdown | 6.34 | 1.54 | +4.80 |
Loading charts...
Drawdowns
BEAM vs. NTLA - Drawdown Comparison
The maximum BEAM drawdown since its inception was -89.12%, smaller than the maximum NTLA drawdown of -96.45%. Use the drawdown chart below to compare losses from any high point for BEAM and NTLA.
Loading charts...
Drawdown Indicators
| BEAM | NTLA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -89.12% | -96.45% | +7.33% |
Max Drawdown (1Y)Largest decline over 1 year | -38.15% | -71.27% | +33.12% |
Max Drawdown (3Y)Largest decline over 3 years | -67.74% | -86.28% | +18.54% |
Max Drawdown (5Y)Largest decline over 5 years | -89.12% | -96.45% | +7.33% |
Max Drawdown (10Y)Largest decline over 10 years | — | -96.45% | — |
Current DrawdownCurrent decline from peak | -73.41% | -91.09% | +17.68% |
Average DrawdownAverage peak-to-trough decline | -59.93% | -57.18% | -2.75% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.72% | 46.25% | -28.53% |
Volatility
BEAM vs. NTLA - Volatility Comparison
The current volatility for Beam Therapeutics Inc. (BEAM) is 23.00%, while Intellia Therapeutics, Inc. (NTLA) has a volatility of 29.13%. This indicates that BEAM experiences smaller price fluctuations and is considered to be less risky than NTLA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BEAM | NTLA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 23.00% | 29.13% | -6.13% |
Volatility (6M)Calculated over the trailing 6-month period | 53.52% | 58.23% | -4.71% |
Volatility (1Y)Calculated over the trailing 1-year period | 75.50% | 99.03% | -23.53% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 76.10% | 81.44% | -5.34% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 80.82% | 78.80% | +2.02% |
Dividends
BEAM vs. NTLA - Dividend Comparison
Neither BEAM nor NTLA has paid dividends to shareholders.
Financials
BEAM vs. NTLA - Financials Comparison
This section allows you to compare key financial metrics between Beam Therapeutics Inc. and Intellia Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
BEAM and NTLA have a correlation of 0.69, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NTLA has higher volatility (29.13%) compared to BEAM (23.00%). In terms of maximum drawdown, BEAM dropped -89.12% vs NTLA's -96.45%.
BEAM currently has the higher Sharpe Ratio (1.49 vs 0.72), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BEAM and NTLA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer